About NeuroKaire
NeuroKaire is a company based in Kearny (United States) founded in 2017 by Talia Cohen Solal and Daphna Laifenfeld.. NeuroKaire has raised $20 million across 6 funding rounds from investors including European Union, GreyBird Ventures and Meron Capital. NeuroKaire offers products and services including AI Precision Platform and Drug Development Service. NeuroKaire operates in a competitive market with competitors including Manus Neuro, Luciole Medical, Rhaeos, RetiSpec and Brain.Space, among others.
- Headquarter Kearny, United States
- Founders Talia Cohen Solal, Daphna Laifenfeld
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Genetikaplus Ltd
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$20 M (USD)
in 6 rounds
-
Latest Funding Round
$10 M (USD), Series A
Dec 17, 2024
-
Investors
European Union
& 7 more
-
Employee Count
Employee Count
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of NeuroKaire
NeuroKaire offers a comprehensive portfolio of products and services, including AI Precision Platform and Drug Development Service. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Uses AI and stem-cells for personalized psychiatry treatment predictions.
Analyzes patient-derived neurons for bio-pharma drug efficacy testing.
Unlock access to complete
Sales and Marketing
2 people
Leadership Team
1 people
COO Team
1 people
Product Management Team
1 people
Unlock access to complete
Funding Insights of NeuroKaire
NeuroKaire has successfully raised a total of $20M across 6 strategic funding rounds. The most recent funding activity was a Series A round of $10 million completed in December 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 6
- Last Round Series A — $10.0M
- First Round First Round
- Investors Count 8
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Dec, 2024 | Amount | Series A - NeuroKaire | Valuation | GreyBird Ventures | |
| Jul, 2022 | Amount | Series A - NeuroKaire | Valuation |
investors |
|
| Jul, 2022 | Amount | Grant - NeuroKaire | Valuation |
investors |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in NeuroKaire
NeuroKaire has secured backing from 8 investors, including venture fund, institutional, and angel investors. Prominent investors backing the company include European Union, GreyBird Ventures and Meron Capital. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Investments are focused on precision diagnostic technologies.
|
Founded Year | Domain | Location | |
|
Meron Capital is focused on investing in technology sectors.
|
Founded Year | Domain | Location | |
|
No company activity is described on the website.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by NeuroKaire
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - NeuroKaire
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Neurokaire Comparisons
Competitors of NeuroKaire
NeuroKaire operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Manus Neuro, Luciole Medical, Rhaeos, RetiSpec and Brain.Space, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Devices for neuromotor impairment biomarkers are provided.
|
|
| domain | founded_year | HQ Location |
Brain monitoring devices and analytics platforms are developed and provided.
|
|
| domain | founded_year | HQ Location |
Noninvasive device developed for CSF monitoring and hydrocephalus management.
|
|
| domain | founded_year | HQ Location |
Non-invasive eye scanner for early Alzheimer’s detection is developed.
|
|
| domain | founded_year | HQ Location |
Brain activity data is analyzed digitally for medical providers.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Neurokaire
Frequently Asked Questions about NeuroKaire
When was NeuroKaire founded?
NeuroKaire was founded in 2017 and raised its 1st funding round 1 year after it was founded.
Where is NeuroKaire located?
NeuroKaire is headquartered in Kearny, United States. It is registered at Kearny, New Jersey, United States.
Who is the current CEO of NeuroKaire?
Talia Cohen Solal is the current CEO of NeuroKaire. They have also founded this company.
Is NeuroKaire a funded company?
NeuroKaire is a funded company, having raised a total of $20M across 6 funding rounds to date.
What does NeuroKaire do?
NeuroKaire was founded in 2017 in Kearny, United States, within the health technology sector focused on central nervous system disorders. A platform is operated to provide personalized treatments for psychiatric and neurological conditions. Stem cell technology, RNA expression, neurobiology, and artificial intelligence are leveraged to support precision medicine. Optimal medications for patients with depression are predicted using a blood test and questionnaire, with operations centered in the United States.
Who are the top competitors of NeuroKaire?
NeuroKaire's top competitors include Brain.Space, RetiSpec and NeuroXess.
What products or services does NeuroKaire offer?
NeuroKaire offers AI Precision Platform and Drug Development Service.
Who are NeuroKaire's investors?
NeuroKaire has 8 investors. Key investors include European Union, GreyBird Ventures, Meron Capital, Jumpspeed, and Sapir Venture Partners.